Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

26.92
-1.0950-3.91%
Post-market: 26.920.00000.00%19:54 EDT
Volume:1.10M
Turnover:29.82M
Market Cap:1.56B
PE:-11.60
High:28.00
Open:27.64
Low:26.60
Close:28.02
52wk High:40.37
52wk Low:4.30
Shares:57.84M
Float Shares:48.42M
Volume Ratio:1.00
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3214
EPS(LYR):-2.2601
ROE:-56.40%
ROA:-31.23%
PB:5.59
PE(LYR):-11.91

Loading ...

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy

TIPRANKS
·
May 15

Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 15

Assessing Capricor Therapeutics (CAPR) Valuation After Strong Multi Year Gains And Recent Share Price Pullback

Simply Wall St.
·
May 14

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
May 13

BRIEF-Capricor Therapeutics Reports First Quarter 2026 Financial Results

Reuters
·
May 13

Capricor Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Capricor Therapeutics Q1 Loss Widens

MT Newswires Live
·
May 13

Capricor Q1 FY26 net loss widens to $33.9 million; revenue remains no revenue

Reuters
·
May 13

Capricor Therapeutics options imply 9.4% move in share price post-earnings

TIPRANKS
·
May 13

Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate

Benzinga
·
May 13

Capricor Therapeutics Inc - No Revenue Recognized for Q1 2026 or Q1 2025

THOMSON REUTERS
·
May 13

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 13

Capricor Therapeutics: Available Cash, Cash Equivalents, Marketable Securities Sufficient to Cover Expenses & Capital Requirements Through Q4 2027

THOMSON REUTERS
·
May 13

Analysts Offer Insights on Healthcare Companies: ImageneBio (IMA) and Capricor Therapeutics (CAPR)

TIPRANKS
·
May 11

Capricor files suit against NS Pharma over Deramiocel distribution deal

TIPRANKS
·
May 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Capricor Therapeutics (CAPR), Enovis (ENOV) and Progyny (PGNY)

TIPRANKS
·
May 09

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Benzinga
·
May 08

H.C. Wainwright Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 08

Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002

Reuters
·
May 08

Capricor Therapeutics Inc - Alleges Ns Pharma Failed to Prepare for Deramiocel Launch and Breached Agreement - SEC Filing

THOMSON REUTERS
·
May 08